Toward the development of rational therapies in multiple sclerosis: what is on the horizon?
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Although the cause of multiple sclerosis (MS) has remained obscure, many findings support an autoimmune pathogenesis on the background of a complex interaction between multiple genes and environmental factors. Accordingly, targeting the immune system has been a rational approach for the treatment of MS. The development of disease‐modifying immunomodulatory drugs with partial efficacy, coupled with advances in understanding the pathophysiology and pathology of MS, has provided momentum to explore more specific and hopefully more effective immune‐based therapeutic strategies. With increased knowledge and appreciation of the contribution of neurodegenerative processes to disease pathology, the therapeutic challenges, however, have become even more formidable. Future treatments will likely need both to target inflammation and to focus on promotion of neuroprotection and repair. In this review, we discuss the most promising therapeutic approaches for MS currently in the pipeline. Ann Neurol 2007
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
Rhen, T., & Cidlowski, J. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050541 · Cited by 3,149 · cited 1×
“Immunosuppression The first breakthrough came with the use of steroids in the treatment of relapses, which shorten the duration of the relapse and may in addition have some longterm effects on disease activity.(14,15) Global immunosuppression with drugs effective in preventing organ transplant rejection, such as azath…”
BackgroundLymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1
Matloubian, M., Lo, C. G., Cinamon, G., Lesneski, M. J., Xu, Y., Brinkmann, V., Allende, M. L., Proia, R. L., & Cyster, J. G. (2004) · Nature · doi:10.1038/nature02284 · Cited by 2,581
The many roles of chemokines and chemokine receptors in inflammation
Charo, I. F., & Ransohoff, R. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052723 · Cited by 2,523 · cited 2×
“The multiplicity of chemokines, their overlapping functions, and their promiscuous binding pattern to numerous receptors displayed on many immune and inflammatory cells, however, represent significant obstacles to successful drug development.(123,124) The redundancy of this system makes it unlikely that blockade of on…”
BackgroundGold, R. (2006) · Brain · doi:10.1093/brain/awl075 · Cited by 1,017 · cited 1×
“More instructive are animal models of autoimmune- or virus-induced demyelination.(1,2) The model most commonly used, experimental autoimmune encephalomyelitis (EAE), has significantly advanced our knowledge of autoimmunity in the central nervous system (CNS) but has unfortunately so far been less successful in deciphe…”
BackgroundThe Promise of Minocycline in Neurology
Yong, V. W., Wells, J., Giuliani, F., Casha, S., Power, C., & Metz, L. M. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00937-8 · Cited by 518
Treatment of multiple sclerosis with the pregnancy hormone estriol
Sicotte, N. L., Liva, S. M., Klutch, R., Pfeiffer, P., Bouvier, S., Odesa, S., Wu, T. C. J., & Voskuhl, R. R. (2002) · Annals of Neurology · doi:10.1002/ana.10301 · Cited by 435
Bettelli, E., Baeten, D., Jäger, A., Sobel, R. A., & Kuchroo, V. K. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28334 · Cited by 336
Inhibition of autoimmune encephalomyelitis by a tetracycline
Popovic, N., Schubart, A., Goetz, B. D., Zhang, S., Linington, C., & Duncan, I. D. (2002) · Annals of Neurology · doi:10.1002/ana.10092 · Cited by 295 · cited 1×
“More recently, based on their chelating properties, tetracyclines and chemically modified tetracyclines were identified to be capable of blocking MMP activity independent of their antimicrobial activity.(127) The tetracycline minocycline has attracted increasing interest as a therapeutic agent for the treatment of var…”
BackgroundEstriol ameliorates autoimmune demyelinating disease: Implications for multiple sclerosis
Kim, S., Liva, S. M., Dalal, M. A., Verity, M. A., & Voskuhl, R. R. (1999) · Neurology · doi:10.1212/wnl.52.6.1230 · Cited by 268
Tiwari-Woodruff, S., Morales, L. B. J., Lee, R., & Voskuhl, R. R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703783104 · Cited by 234
Cited by
Remyelination in the CNS: from biology to therapy
Franklin, R. J. M., & ffrench-Constant, C. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2480 · Cited by 1,544
“However, the clinical application of increasingly effective anti-inflammatory drug”
BackgroundMechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
Chun, J., & Hartung, H.-P. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181cbf825 · Cited by 796
“Most current disease-modifying therapies (DMTs) for MS primarily target the immunological inflammatory component of the disease without acting directly on the CNS; such DMTs have been shown to be only partially effective.(12) First-line DMTs, interferon A-1a or A-1b (IFNA-1a or IFNA-1b, respectively) and glatiramer ac…”
BackgroundSelf-citationThe genetics of multiple sclerosis: SNPs to pathways to pathogenesis
Oksenberg, J. R., Baranzini, S. E., Sawcer, S., & Hauser, S. L. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2395 · Cited by 347
“Current MS therapies are all immunomodulatory; that is, they partially protect against relapses but are ineffective against purely progressive symptom”
Background
Metadata
- Authors
- Hemmer, B., & Hartung, H.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2007-10
- Volume
- 62
- Issue
- 4
- Pages
- 314-326
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2113275840
- Cited by
- 70
- References
- 11
- FWCI
- 7.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Toward the development of rational therapies in multiple sclerosis: what is on the horizon? https://app.cochat.ai/papers/10.1002/ana.21289
- The paper
- Hemmer, B., & Hartung, H. (2007). Toward the development of rational therapies in multiple sclerosis: what is on the horizon? Annals of Neurology. https://doi.org/10.1002/ana.21289
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.